Melbourne, Australia-based Telix Pharmaceuticals reported a spike in revenue for the second quarter of 2024, citing strong sales of Illuccix (gallium-68 prostate-specific membrane antigen [PSMA]-11), its PSMA-PET radiotracer kit for prostate cancer imaging.
For the second quarter (end-June 30), the company reported unaudited total revenue of 189 million Australian dollars ($126 million U.S.), an increase of 55% over the same period in 2023 and an increase of 8% over the first quarter in 2024. Revenue generated from U.S. Illuccix sales was approximately 184 million Australian dollars ($123 million U.S.), the company said.
